Lentiviral vectors have valuable capabilities in gene therapy. This is mainly due to their low immunogenicity and ability to transduce both dividing and non-dividing cells with high efficiency. They are Non replicative and Nonpathogenic (all the virulence genes have been deleted).Lentiviral vectors can achieve long-term and stable expression of the transgene, this gives them a wide range of potential therapeutic applications.
Our innovative lentiviral vectors enable dendritic cells to train immune cells to destroy infected cellsor cancer cells.
Our lentiviral vectors can efficiently transduce dendritic cells and thus elicit a protective cellular immuneresponse. Antigens are presented in a sustained manner through the endogenous pathway, subsequently leading to physiological activation and maturation of key immune effectors and cytotoxic activity of T-cells, with unprecedented efficacy.
A lentiviral vector carries antigen genes from a pathogen or tumor cell.
The lentiviral vector transcripts and releases the mRNA that encodes the antigen into the dendritic cell.
Dendritic cells presents the antigens to T cells.
T cells recognize the antigens and kill the antigen-bearing cells (pathogens, infected or tumor cells).
* Research on viral vectors had led to the discovery of DNA FLAP, a 99 nucleotides sequence that is unique and necessary for the pre-integration complex of the virus to cross the membrane of the nucleus of the non-dividing cells it infects. This DNA Flap therefore accounts for the mitosis-independent replication of lentiviruses.
* Our vectors have a strong proclivity to infect dendritic cells, which are the most ideal cells to mount a proper T cell immune response.* Our vectors contain DNA flap technology, enabling the virus to cross the nucleus membrane and get into the cell nucleus, so that they can also transfer genes into non-dividing cells. Dendritic cells are non-dividing.* We offer both non-integrative and integrative vectors.* Our vectors induce a sustained exposure of antigens by dendritic cells (a process called endogenous antigen presentation). This long-standing exposure enables a strong T cell and antibody-mediated immune response.* Our vectors elicit a natural immune response.* Our vectors enable a strong long-lasting memory response and control mechanisms (return to normal conditions after elimination of the pathogen or cancer cells).* Our vectors elicit a strong T cell response. T cells are much better at destroying intracellular organisms than antibodies.* Jinwei has an extensive pipeline targeting HBV, tuberculosis, prostate cancer, liver cancer and other various solid cancers.* Jinwei has obtained exclusive license of multiple patents and other intellectual property, including exclusive rights for lentiviral vector manufacturing and developing using DNA flap mechanisms.
We develop leading edge therapies for various cancers by combining next-generation In-Silico Neoantigen identification methods with built-in lentiviral vector-based platform.
The current oncological indications are liver and prostate cancer therapies which are personalized treatment through targeting specific genetic aberrations harbored by each patient's tumor.